The FDA approval makes PD-L1 IHC 22C3 pharmDx the only companion diagnostic approved to detect tumors expressing PD-L1 in esophageal or GEJ carcinoma patients for KEYTRUDA treatmen
The global, first-in-human, open-label trial will assess the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of TRI-611
Iza-bren met both dual primary endpoints, delivering statistically significant and clinically meaningful improvements in progression-free survival
Zongertinib is setting a new standard as the first targeted therapy for treatment naïve patients with HER2-mutant advanced non-small cell lung cancer with demonstrated efficacy
The partnership will focus on the ongoing SYNERGY-101 randomized Phase 2 trial for first-line
The Japanese Patent Office has issued a favorable Appeal Decision granting a patent for the use of REQORSA Gene Therapy in combination with PD-L1 antibodies to treat cancer
Sugemalimab, developed using CStone’s OmniRat transgenic platform, is a fully human IgG4 monoclonal antibody designed to minimize immunogenicity and toxicity
To support this launch, ImmunityBio has established a wholly owned subsidiary in Saudi Arabia
The drug’s safety profile in LIBRETTO-432 aligned with previous selpercatinib studies, showing no unexpected concerns
This approval builds on the recent transformation RYBREVANT FASPRO brought to lung cancer care
Subscribe To Our Newsletter & Stay Updated
